Nano Science and Technology Institute

Midatech Creates PharMida AG, A New Subsidiary Applying Nanotechnology to Drug Discovery

Midatech, a company that focuses on the design, synthesis, and manufacture of biocompatible nanoparticles, recently announced the formation of a Basel-based Swiss drug development subsidiary, PharMida AG. The subsidiary follows an important investment by a group of Switzerland-based investors into Midatech Ltd. The mission of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. PharMida will have the responsibility to project manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage the collection of the already existing Midatech Ltd product lines in Life Sciences.

↑ Back to Nano World Breaking News™

↑ Back to Nano World News™

Nano World News™ Issue Archive:

RSS feed RSS feed

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map